• Explore /
  • Poster
  • / Phase I trial of α-particle therapy with actinium-225 (<sup>225</sup>Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Phase I trial of α-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Abstract Poster

Authors

null

Joseph G. Jurcic

Columbia University Medical Center, New York, NY

Joseph G. Jurcic , Farhad Ravandi , John M. Pagel , Jae Hong Park , B. Douglas Smith , Dan Douer , Moshe Yair Levy , Elihu Estey , Hagop M. Kantarjian , Dennis Earle , Dragan Cicic , David A. Scheinberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCI-2014-01360, NCT01756677

Citation

J Clin Oncol 33, 2015 (suppl; abstr 7050)

DOI

10.1200/jco.2015.33.15_suppl.7050

Abstract #

7050

Poster Bd #

39

Abstract Disclosures

Similar Posters

First Author: Anthony J. Chalmers

First Author: Daniel J. DeAngelo

Poster

2016 ASCO Annual Meeting

Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.

Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.

First Author: Maro Ohanian

First Author: Maria Creselda deLeon